Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo

被引:116
作者
Shi, L. [1 ]
Xiong, H. [1 ]
He, J. [1 ]
Deng, H. [1 ]
Li, Q. [1 ]
Zhong, Q. [1 ]
Hou, W. [1 ]
Cheng, L. [1 ]
Xiao, H. [1 ]
Yang, Z. [1 ]
机构
[1] Wuhan Univ, Inst Med Virol, State Key Lab Virol, Wuhan 430071, Peoples R China
关键词
D O I
10.1007/s00705-007-0974-5
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Arbidol, ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-in dole-3-carboxylate hydrochloride monohydrate, is an antiviral chemical agent. In this report, we studied the antiviral activity of arbidol against a panel of human respiratory viruses, namely influenza A virus (FLU-A, A/PR/8/34 H1N1), respiratory syncytial virus (RSV), human rhinovirus type 14 (HRV 14), coxsackie virus B3 (CVB3) and adenovirus type 7 (AdV-7) in vitro in cell culture. Arbidol was found to present potent inhibitory activity against enveloped and non-enveloped RNA viruses, including FLU-A, RSV, HRV 14 and CVB3 when added before, during, or after viral infection, with 50% inhibitory concentration (IC50) ranging from 2.7 to 13.8 mu g/ml. However, arbidol showed selective antiviral activity against AdV-7, a DNA virus, only when added after infection (therapeutic index (TI) = 5.5). Orally administered arbidol at 50 or 100 mg/kg/day beginning 24 h pre-virus exposure for 6 days significantly reduced mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Our results suggest that arbidol has the ability to elicit protective broad-spectrum antiviral activity against a number of human pathogenic respiratory viruses.
引用
收藏
页码:1447 / 1455
页数:9
相关论文
共 34 条
[1]   Arbidol:: a broad-spectrum antiviral that inhibits acute and chronic HCV infection [J].
Boriskin, Yury S. ;
Pecheur, Eve-Isabelle ;
Polyak, Stephen J. .
VIROLOGY JOURNAL, 2006, 3 (1)
[2]   Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? [J].
Brooks, MJ ;
Sasadeusz, JJ ;
Tannock, GA .
CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (03) :197-203
[3]   Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice [J].
Burger, RA ;
Billingsley, JL ;
Huffman, JH ;
Bailey, KW ;
Kim, CU ;
Sidwell, RW .
IMMUNOPHARMACOLOGY, 2000, 47 (01) :45-52
[4]   Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates [J].
Chai, HF ;
Zhao, YF ;
Zhao, CS ;
Gong, P .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (04) :911-917
[5]  
Fedyakina I. T., 2005, Voprosy Virusologii, V50, P32
[6]   RESPIRATORY SYNCYTIAL VIRUS OR INFLUENZA [J].
FLEMING, DM ;
CROSS, KW .
LANCET, 1993, 342 (8886-7) :1507-1510
[7]   Antirhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives [J].
Garozzo, A ;
Cutrì, CCC ;
Castro, A ;
Tempera, G ;
Guerrera, F ;
Sarvà, MC ;
Geremia, E .
ANTIVIRAL RESEARCH, 2000, 45 (03) :199-210
[8]   Association of rhinovirus infections with asthma [J].
Gern, JE ;
Busse, WW .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (01) :9-+
[9]  
GUSKOVA TA, 1999, CHEM PHARM J, V6, P14
[10]   Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis [J].
Hayden, FG ;
Belshe, R ;
Villanueva, C ;
Lanno, R ;
Hughes, C ;
Small, I ;
Dutkowski, R ;
Ward, P ;
Carr, J .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (03) :440-449